Page 1

NEWS RELEASE charles river CHARLES RIVER LABORATORIES ANNOUNCES FIRST - QUARTER 2021 RESULTS - First - Quarter Revenue of $ 824.6 Million - - First - Quarter GAAP Earnings per Share of $ 1.20 and Non - GAAP Earnings per Share of $ 2.53 - - Updates 2021 Guidance - WILMINGTON , MA , May 4 , 2021 – Charles River Laboratories International , Inc. ( NYSE : CRL ) today reported its results for the first quarter of 2021. For the quarter , revenue was $ 824.6 million , an increase of 16.6 % from $ 707.1 million in the first quarter of 2020 . Acquisitions contributed 0.7 % to consolidated first - quarter revenue growth . The impact of foreign currency translation benefited reported revenue growth by 2.9 % . Excluding the effect of these items , organic revenue growth of 13.0 % was driven by contributions from all three business segments . The year - over - year comparison to last year's COVID - 19 - related revenue impact contributed approximately 140 basis points to the reported and organic revenue growth rates in the first quarter , principally in the Research Models and Services segment . On a GAAP basis , first - quarter net income attributable to common shareholders was $ 61.5 million , an increase of 21.2 % from net income of $ 50.8 million for the same period in 2020 . First - quarter diluted earnings per share on a GAAP basis were $ 1.20 , an increase of 17.6 % from $ 1.02 for the first quarter of 2020. The increases in the GAAP net income and earnings per share were driven primarily by higher revenue and operating margin improvement , partially offset by debt extinguishment costs and the write - off of deferred financing costs related to debt refinancing activities in the first quarter of 2021 . On a non - GAAP basis , net income from continuing operations was $ 129.2 million for the first quarter of 2021 , an increase of 40.7 % from $ 91.8 million for the same period in 2020 . First - quarter diluted earnings per share on a non - GAAP basis were $ 2.53 , an increase of 37.5 % from $ 1.84 per share for the first quarter of 2020. The non - GAAP net income and earnings per share increases were driven primarily by higher revenue and operating margin improvement . James C. Foster , Chairman , President and Chief Executive Officer , said , “ Our first - quarter performance demonstrates the power of our unique , non - clinical portfolio and the strength of the biopharmaceutical market environment . A global focus on scientific innovation driving record levels of investment in the biopharmaceutical industry , which is generating biomedical 1